Publications from the Centre for Immuno-Oncology
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Skolariki A. et al, (2025), Mol Oncol
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Vadibeler S. et al, (2025), Matrix biology : journal of the International Society for Matrix Biology
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future oncology (London, England), 21, 195 - 200
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2024), Nat Rev Immunol
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), The Lancet. Oncology, 25, 1476 - 1486
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.
Gregorczyk M. and Parkes EE., (2023), DNA repair, 132
Non-cell-autonomous cancer progression from chromosomal instability.
Li J. et al, (2023), Nature, 620, 1080 - 1088
Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1.
Sugiyarto G. et al, (2023), Journal for immunotherapy of cancer, 11
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J. et al, (2023), Molecular cancer, 22
cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Beernaert B. and Parkes EE., (2023), Biochemical Society transactions, 51, 539 - 555
Investigating the effects of homologous recombination deficiency on radiotherapy response in pre-clinical prostate cancer
Kwon J. et al, (2023), EUROPEAN UROLOGY, 83
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Calvo E. et al, (2023), ANNALS OF ONCOLOGY, 34, S626 - S626
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
Fletcher CE. et al, (2022), Molecular cancer, 21
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends in cancer, 8, 174 - 189
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), British journal of cancer, 126, 247 - 258
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments
Kopetz S. et al, (2022), JOURNAL OF CLINICAL ONCOLOGY, 40